RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact
Open Access
- 1 December 2009
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (12) , 4735-4741
Abstract
Context: Poorly differentiated carcinomas represent an aggressive group of thyroid tumors with controversial classification placement and poorly understood pathogenesis. Molecular data in this group of tumors are extremely heterogeneous, possibly reflecting different inclusion criteria. Recently homogeneous diagnostic criteria have been proposed by our group (Turin proposal) that need to be complemented by detailed molecular characterization. Objective: The objective of the study was to define a comprehensive molecular typing of poorly differentiated thyroid carcinomas classified following homogeneous diagnostic criteria. Design: Sixty-five cases of poorly differentiated carcinoma selected following the Turin proposal have been screened for N-, K-, H-RAS, BRAF, RET/PTC1 and 3, and PAX8/PPARγ mutations-rearrangements using alternative techniques and in two different laboratories. Molecular data were compared with clinical pathological parameters and survival by univariate and multivariate analysis. Results: RAS mutations in codon 61 were by far the most common genetic alteration in poorly differentiated carcinomas (23% of cases), with all mutation in NRAS except one in the HRAS gene. A single BRAF mutation was found in a poorly differentiated carcinoma with a residual component of a tall cell variant of papillary carcinoma. No KRAS, RET/PTC, or PAX8/PPARγ genetic alteration was detected. In this series, the presence of RAS mutations was a unique negative prognostic parameter at multivariate analysis. Conclusions: The present study demonstrates that strictly classified poorly differentiated carcinomas are genetically homogeneous, RAS mutations being the almost exclusive genetic event. Moreover, the detection of RAS mutations might be clinically relevant for the prognostic stratification of these tumors.Keywords
This publication has 33 references indexed in Scilit:
- Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial IssuesEndocrine Pathology, 2008
- Clinical Features and Prognostic Factors for Survival in Patients with Poorly Differentiated Thyroid Carcinoma and Comparison to the Patients with the Aggressive Variants of Papillary Thyroid CarcinomaEndocrine Journal, 2007
- Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomasClinical Endocrinology, 2006
- Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosisCancer, 2006
- Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patternsCancer, 2004
- Poorly Differentiated Carcinomas of the Thyroid GlandInternational Journal of Surgical Pathology, 2002
- Insular CarcinomaAmerican Journal of Surgical Pathology, 1997
- Poorly Differentiated Thyroid Carcinomas with Primordial Cell ComponentAmerican Journal of Surgical Pathology, 1993
- Poorly differentiated (“insular”) thyroid carcinomaAmerican Journal of Surgical Pathology, 1984
- Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomasCancer, 1983